For as long as most of us have been quietly counting the times we walked into a room and forgot why, getting a real answer has meant getting into a memory clinic. A referral, a waiting list, a PET scan or a spinal tap. Last week in London, researchers reported something that changes the shape of that problem — and the most useful part of the finding is not the part the headlines led with.
Today: why your family doctor just got much better at this, what a two-year study in eleven countries found about the kind of help that actually works, a scam that hides in plain sight at the top of your search results, what one state now requires an assisted-living contract to say, and the two Moon flights one generation got to watch.
📰 The Big Story
Your Family Doctor Just Caught Up to the Specialist
At the Alzheimer's Association International Conference in London on Monday, a team from Lund University in Sweden reported the results of something nobody had really done before: they took a blood test for Alzheimer's out of the research clinic and handed it to ordinary doctors in ordinary practices, then measured what happened.
The setup matters, so here it is plainly. 1,310 patients in Sweden with memory problems — either mild cognitive impairment or dementia — were evaluated by 165 physicians. Most were seen by dementia specialists. 383 were seen by primary care doctors, and those patients were also independently assessed by specialists, which means the researchers could put a family doctor and a specialist side by side on the same patient and see who got it right. Accuracy was judged against spinal fluid analysis, amyloid PET imaging, and a consensus diagnosis by dementia experts.
Take the primary care patients first, since they are the ones this is really about. Before their doctors saw any blood test result, those family doctors got the diagnosis right 65% of the time. After they saw it, 93%. And the specialists who independently assessed those same patients landed at 94%.
That is the number that matters, because it is the only true side-by-side: same patients, same week, one point apart.
Across the much larger group of patients seen in specialist clinics — a separate set of 927 people, not the same ones — specialists went from 74% to 89% with the test. Useful, but a smaller jump, and for an obvious reason: they were already good at this.
Translation: the test didn't make specialists dramatically better. It made everybody else nearly as good as a specialist. The gap that referrals and waiting lists exist to close mostly disappeared when a family doctor had a blood test result in hand.
Now the part worth reading twice. The single most valuable thing the test did in primary care was not tell doctors that someone had Alzheimer's. It was tell them that someone didn't.
After a negative result, primary care doctors' willingness to rule Alzheimer's out roughly doubled, from 12.9% to 25%. They changed the diagnosis in 30% of patients, and changed the plan — referrals, further testing, treatment — in about half of all cases. "A negative result helped primary care physicians confidently rule out Alzheimer's and look for other causes of the symptoms," said Dr. Sebastian Palmqvist, the neurologist at Lund University who led the study.
Why this matters: a great many people with memory complaints do not have Alzheimer's. They have a thyroid problem, or a B12 deficiency, or sleep apnea, or depression, or a medication interaction — things that are treatable, and things that go untreated while everyone assumes the worst and waits nine months for a scan. A test that quickly says look somewhere else is worth as much as one that says look here.
Can you actually get this in the United States? Partly, and the distinction matters. The specific test used in the Swedish study, PrecivityAD2, is not FDA-cleared. But since October 13, 2025, there has been an FDA-cleared blood test built for exactly this job: Roche's Elecsys pTau181, cleared specifically for use in primary care to help rule out the amyloid buildup associated with Alzheimer's. It's for adults 55 and older who already have symptoms or complaints of cognitive decline, and in the study behind its clearance it correctly identified people unlikely to have Alzheimer's pathology with a 97.9% negative predictive value. An earlier test, Lumipulse, was cleared in May 2025 for symptomatic adults evaluated in specialty settings.
What to do: if memory is the thing you have been meaning to bring up, bring it up with your regular doctor rather than waiting for a specialist appointment — and ask directly whether a blood biomarker test is appropriate for you. If you are not sure whether what you are noticing warrants the conversation at all, we walked through the difference between normal aging and something more — that's the piece to read first.
Four honest cautions, because this is the part that gets lost:
- These tests are for people with symptoms. None of them is a screening test for people who feel fine and are worried. That is not what they were cleared for and not what they were studied for.
- A blood test is not a diagnosis. There is no stand-alone test for Alzheimer's. It is one piece, used alongside your history, an exam, and cognitive testing.
- A negative result does not mean nothing is wrong. These tests look for Alzheimer's specifically. Palmqvist's own caution: people with negative results may still have another neurological condition and may still need a specialist.
- Not all of these tests are equally good. "Because not all blood-based biomarker tests meet the same standards for accuracy, clear evidence-based guidance is essential," said Dr. Sheena Aurora of the Alzheimer's Association, which publishes clinical practice guidelines for doctors on which test to use when.
Editor's note added August 31, 2026: two things happened after this issue that readers should know. On August 20, the FDA cleared PrecivityAD2 — the test used in the study above — for adults 40 and older with symptoms of cognitive impairment, making it the third such blood test cleared and the first cleared for people that young. Four days later, on August 24, the FDA cleared a fourth, Roche's Elecsys pTau217. Everything above about how to use these tests, and who they are and are not for, is unchanged.
📡 On Your Radar
Three short things worth knowing.
💃 A two-year study says the coaching mattered more than the advice. Also out of last week's conference, and published in The Lancet on July 13: researchers enrolled 1,065 adults aged 60 to 77 at elevated risk of dementia, across eleven Latin American countries, and ran them for two years. Everyone got the same ingredients — exercise, dietary guidance, cognitive training, social engagement, and regular heart-health monitoring. The difference was delivery. One group got a structured, supervised program with coaching; the other got periodic health advice and freedom to use it. Both groups' cognitive scores improved. But the structured group improved about 55% more on overall thinking ability, with the largest gains in episodic memory — the everyday kind, where you left the keys, what your daughter said on Sunday. The takeaway: this is not "lifestyle prevents dementia," and the study does not claim that; both groups did the same things. It is a study about the difference between being told and being coached. Worth knowing before you pay for anything that is only a list of instructions. (A charming footnote: the program was adapted to local culture, so salsa and tango counted as the exercise.)
🔍 The scam is sitting above the real result. The FTC put out an alert on July 20 about people searching online for treatment clinics and landing on scammers instead — and the mechanism is the part to carry with you, because it has nothing to do with clinics. Here is the part that makes it work, and it is worse than most people picture. The scammers buy the paid ad slot and run the real organization's own name in the ad — then swap in their own website link and phone number underneath it. So there is no odd spelling to catch, no unfamiliar company to notice. In the FTC's words, "the top search result looked like the clinic's listing," and you wouldn't realize it's a paid ad at all. You search the right name, you see the right name, you click the top result, and you reach the wrong people. What to do: when you go looking for a customer service number, a bill-payment page, or a government office, scroll past the results marked "Sponsored" or "Ad" before you click anything — or skip the search entirely and type the address you already know, or use the number printed on your own statement or card.
📋 One state just wrote down what an assisted-living contract has to say. As of July 17, Massachusetts assisted-living residences operate under the first consumer-protection regulations of their kind in the state — announced by Attorney General Andrea Joy Campbell in the year after the Gabriel House fire in Fall River, which killed 10 residents in July 2025. Residences must provide plain service agreements that state what services cost and the conditions under which those costs can rise; must be clear about what happens if a resident can no longer afford to stay or comes to need care the residence cannot give; must disclose what nursing care is actually available on site; and must extend residents tenant-style protections around fees and eviction. A separate set of state safety rules — annual fire-department inspections, quarterly drills, and AEDs, naloxone and epinephrine at every residence — is scheduled to take effect July 31. The rules cover 272 residences. Why this matters even if you don't live in Massachusetts: somebody has now written down, in enforceable language, what a fair assisted-living agreement looks like. Take that list to any tour, in any state, and ask for each item in writing.
💡 Worth Knowing
"It's just aging" is an answer you're allowed to push on
Everything in the big story assumes the appointment goes well. Often it doesn't. The most common thing we hear from readers is not that a doctor got a diagnosis wrong — it's that a symptom got waved off before anyone looked into it. Slower walking, a new tremor, forgetting words, exhaustion, a shoulder that stopped working. That's just part of getting older.
Sometimes that is true. Often it is a shortcut, and it is the reason treatable things go untreated for years.
The useful move is not to argue. It's to ask one specific question that changes what happens next: "If this weren't aging, what would it be — and how would we tell the difference?" That question asks for a differential rather than a verdict, and most doctors will answer it. It's also the question that gets a blood test, a thyroid panel, or a B12 level ordered rather than deferred.
We put together the full version — what to say, what to bring, and how to ask for it in writing when the answer is still no.
Read the "it's just aging" guide →
📖 From the Archives
When Sudden Confusion Isn't What Everyone Assumes
The whole point of the big story is that the reflex explanation is often the wrong one. Here is the version of that problem families actually run into, and it runs in both directions.
An older parent goes suddenly foggy — confused, agitated, not themselves — and somebody says it's probably a urinary tract infection. Sometimes that's right, and the antibiotics fix it in two days. Sometimes it's a guess that stops anyone from looking for what's really happening, which with sudden confusion can be a medication, dehydration, low sodium, a small stroke, or pain nobody has located. Sudden is the operative word: Alzheimer's does not arrive over a weekend. Anything that does is a different problem and often an urgent one.
We wrote up how to tell the difference, and why a careful doctor may deliberately not reach for the antibiotics.
Read the sudden-confusion guide →
☕ Slice of Life
Fifty-seven years ago yesterday — July 20, 1969 — the Eagle landed, and a very large number of people who are reading this were sitting on a living room floor in front of a television set watching it happen.
Here is the thing about that. For fifty-three years afterward, nobody went back. Apollo 17 came home in December 1972 and that was the end of it; every human being since has stayed in low Earth orbit, a few hundred miles up, closer to the ground than Boston is to Chicago.
Then, on April 1 of this year, four astronauts — Reid Wiseman, Victor Glover, Christina Koch and Canada's Jeremy Hansen — launched on Artemis II, swung around the far side of the Moon, and splashed down in the Pacific nine days and about ninety minutes later. NASA's own description of the flight: they went farther from Earth and closer to the Moon than any human has been in over half a century.
Which means that if you watched Armstrong come down that ladder, you have now seen both. The first time anyone went, and the first time anyone went back. Most generations don't get one of those.
That's the week. If memory is the thing you've been meaning to mention, mention it — the appointment is a shorter road than it used to be.
— Nino
P.S. The ruling-out finding in the big story is the one I'd pass along. Somebody in your life is quietly assuming the worst about a parent, or about themselves, and hasn't asked anyone because they think the answer takes six months and a scan. Forward this to them. I read every reply.
